WO2004082704A1 - 骨破壊を伴う炎症性疾患の治療方法 - Google Patents
骨破壊を伴う炎症性疾患の治療方法 Download PDFInfo
- Publication number
- WO2004082704A1 WO2004082704A1 PCT/JP2004/002887 JP2004002887W WO2004082704A1 WO 2004082704 A1 WO2004082704 A1 WO 2004082704A1 JP 2004002887 W JP2004002887 W JP 2004002887W WO 2004082704 A1 WO2004082704 A1 WO 2004082704A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- vector
- virus
- bone
- protein
- fgf2
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a method for controlling the function of fibroblast growth factor-2 (FGF2), and for treating an inflammatory disease associated with bone rupture by blocking its intracellular signal transduction system.
- FGF2 fibroblast growth factor-2
- the method of the present invention is particularly useful for treating rheumatoid arthritis (RA).
- RA treatment strategies Various treatment strategies and disease-modifying properties for RA based on global medical research so far! ] (disease modifyttg anti rheumatoid drugs: DMARDs)
- DMARDs disease modifyttg anti rheumatoid drugs
- TNF tumor necrotic factor
- Soluble 'soluble VEGF receptor (Miotla, J. et al., Lab. Invest., 80: 1195-205 (2000)) or anti-VEGF antibody (Lu, J. et al., J. Immunol. 164: 5922). -7 (2000); Sone, H. et al., Biochem. Biophys. Res. Coramun. 281: 562-8 (2001)) to treat RA by inhibiting the function of VEGF. This is a cytokine therapy.
- the present invention provides a method for treating an inflammatory disease associated with bone destruction by inhibiting the function of FGF2 or blocking its intracellular signal transduction system.
- the present invention also provides a therapeutic composition for the disease, comprising a vector encoding a protein that inhibits the function of FGF2 or blocks its intracellular signal transduction system.
- FGF2 is a growth factor that plays an important role in the development of cells (Klansbrun, M., 1989, Prog. Growth Factor Res. 1: 207-235; Mason, I., 1994, Cell 78). Bikfalvi, A. et al., 1997, Endocr. Rev. 18: 26-45).
- FGF2 plays an important role in normal developmental processes and tissue regeneration via the FGF receptor (FGFR), and is also involved in cancer growth and inflammation (Basilico, C. and Moscatelli, D, 199 2, Adv. Cancer Res. 59: 115-165; Klein, S et al., 1997, Experientia Suppl.
- FGFR FGF receptor
- FGF2 When FGF2 binds to FGFR, downstream signal molecules are phosphorylated by the tyrosine phosphorylation activity of FGFR, and signals are transmitted to Ras, Raf-1, MAPKK, and MAPK.
- the present inventors have considered applying gene therapy that inhibits signal transduction using a vector that expresses a gene that inhibits signal transduction to inflammatory bone diseases.
- the present inventors have prepared a secretory FGF receptor that inhibits the function of FGF2, and a viral vector encoding sprouty-2 and spred that block the intracellular signal transduction system of FGF2.
- Gene therapy was administered to the joints.
- inflammation of joints was significantly suppressed by administration of any of these vectors, and further, bone loss was reduced in joints to which the vector was administered, and significant treatment was achieved.
- the effect was recognized.
- a vector that expresses a protein that inhibits the function of FGF2 or blocks its intracellular signal transduction system to the site of a bone disease, it suppresses inflammation at the site of the disease and at the same time suppresses bone rupture. was significantly improved.
- the present invention relates to a method for treating an inflammatory disease accompanied by bone destruction by inhibiting the function of FGF2 or blocking its intracellular signal transduction system, and a pharmaceutical composition used for the treatment, more specifically, The invention described in each of the claims. It is to be noted that the present invention also contemplates inventions comprising one or more (or all) desired combinations of the inventions described in the claims. That is, the present invention more specifically
- a method for treating an inflammatory disease associated with bone destruction comprising fibroblast growth factor-2 (FGF2) -one FGF receptor-one Ras_Raf—a protein or nucleic acid that inhibits MAP kinase-mediated signal transduction
- FGF2 fibroblast growth factor-2
- Ras_Raf a protein or nucleic acid that inhibits MAP kinase-mediated signal transduction
- Stringent hybridization conditions include, for example, 5X SSC, 7% (W / V) SDS, 100 / zg / ml denatured salmon sperm DNA, Liquid (1X Denhardt's solution contains 0.2% polyvinylpyrrolidone, 0.2% bovine serum albumin, and 0.2% ficoll) at 48 ° C, preferably 50 ° C, Preferably, the hybridization is carried out at 52 ° C, and then at the same temperature as the hybridization, more preferably at 60 ° C, more preferably at 65 ° C, most preferably at 68 ° C in 2X SSC, preferably at 1 ° C. In XSSC, more preferably in 0.5 X SSC, more preferably in 0.1 X SSC, the condition is that washing is performed for 2 hours with shaking.
- Recombinant negative-strand RNA virus vectors are constructed by constructing recombinant DNA in which a suitable transcription promoter is linked to DNA encoding the viral genome, and then transcribed in vitro or in a cell.
- the RP can be produced by reconstituting the RP in the presence of the NP protein and the NP protein to form a virus particle containing the RNP.
- a negative strand RNA a vector DNA encoding a single-stranded negative strand RNA derived from Inores or its complementary strand (positive strand) is used for cells expressing NP, P, and L proteins
- B culturing the cells, and collecting virus particles from the culture supernatant.
- desired paramyxovirus vectors including parainfluenza, vesicular stomatitis virus, rabies virus / res, measles virus, Linda-Pestuinores, Sendai innores, etc., and other (-) chain-activated virus vectors
- One can be reconstituted from DNA. Negative strand RNA virus is expressed
- the amount of proteins that can be transferred is extremely high, and the cell types that can be transfected are extremely wide.
- Sendai virus (SeV) has no serious adverse effects in primates and is suitably used in the present invention for gene therapy in humans (Hurwitz, JL et al., Vaccine 15: 533-540). , 1997).
- the recovered virus vector can be purified to be substantially pure.
- the purification can be performed by a known purification / separation method including filtration, centrifugation, column purification and the like, or a combination thereof.
- substantially pure refers to the fact that the viral vector makes up the major proportion of the components in the sample in which it is present.
- a substantially pure viral vector contains at least 10% of the protein derived from the viral vector out of all proteins contained in the sample (excluding proteins added as carriers and stabilizers). It can be confirmed by occupying preferably at least 20%, more preferably at least 50%, preferably at least 70%, more preferably at least 80%, further preferably at least 90%.
- FGF2 the target molecule in the present invention, is not only a biological agent as an angiogenic factor, but also a factor promoting osteoclast differentiation and function that plays a central role in bone destruction. I have. Therefore, by controlling the function of FGF2, it is possible to not only suppress the development of synovitis but also directly inhibit osteoclast differentiation and function. Both phenomena such as destruction can be suppressed.
- a protein preparation that is effective against RA When a protein preparation that is effective against RA is administered systemically orally or intravenously, 1) the drug reaches the local area of the synovium, 2) the effective concentration is obtained locally, and 3) side effects occur in various organs. Significant problems to be solved remain, such as expression.
- a therapeutic gene is expressed in synovial tissue using a vector, so that an effective gene expression level at the joint site can be continuously obtained for a certain period of time. It becomes possible. By using this gene therapy technique, it is possible to avoid high concentrations of protein locally or systemically.
- the present invention includes a method of administering a vector into which a gene that suppresses the function of FGF2, or a gene that blocks the intracellular fermentation system of FGF2 receptor or higher, has been incorporated.
- the selective inhibition of a single enzyme in the intracellular signal transduction system enables the production and treatment of a therapeutic agent that is more specific for a disease or condition.
- the present invention enables an ideal biological drug discovery that selectively inhibits a disease-specific molecule.
- the dose of the vector varies depending on the disease, the patient's body weight, age, sex, symptoms, purpose of administration, form of administration composition, administration method, transgene, etc., but can be appropriately determined by those skilled in the art. is there.
- the route of administration can be selected as appropriate, but is locally injected so as to specifically reach the affected area with osteolytic inflammation, or administered using a suitable drug delivery system to reach the affected area. It is preferable.
- paramyxovirus vector properly preferred concentration of vector administered is about 10 5 CIU / ml to about 10 11 fu / ml, more preferably about 10 7 CIU / ml to about 10 9 CIU / ml, most Preferably, an amount in the range of about 1 ⁇ 10 8 CIU / ml to about 5 ⁇ 10 8 CIU / ml is administered in a pharmaceutically acceptable carrier.
- PBS phosphate buffered saline
- FBS 10% fetal bovine serum
- Rat bone marrow-derived macrophages were isolated by this method M- CSF dependent foot Hone ⁇ macrophage 1 emission (M-CSr - dependent bone marrow macrophages: MDBM) was defined.
- MBD Mycobacterium Butyricum Desiccated
- NACALAI TESQUE Kyoto
- the target gene was expressed locally in the inflammation by a direct gene transfer method into rats using a recombinant Sendai virus vector (SeV), and the effect on arthritis was examined. Specifically, the onset of arthritis was confirmed.
- Hind paw volume (hpv) was measured over time using a volume meter (MK-550; Muromachi Kikai, Tokyo) to quantify hind limb swelling due to arthritis.
- Figure 2A shows the hind limb volume over time.
- the hind limb volume on Day 21 was 3.06 in the AIA + sFGFR group, 0.13 in the AIA + luciferase group, 3.93 ⁇ 0.11 ml in the AIA + suciferase group, and on Day 28, 2.85 ⁇ 0 in the AIA + sFGFR group.
- the AIA + ludferase group was 3.29 ⁇ 0.12 ml.
- hind limb swelling was significantly suppressed by FGF-2 extracellular signal blockade by sFGFR gene transfer.
- Figure 2B shows the volume change rate from Dayl4 to Day21.
- the AIA + sFGFR group was 0.18 ⁇ 0.07 and the AIA + ludf erase group was 0.86 ⁇ 0.09 ml. It was significantly suppressed by signal block.
- Figure 2C shows the radiographic bone and joint rupture index.
- bone / joint destruction due to FGF-2 extracellular signal blockade on Day 28 Significantly suppressed
- the rats were sacrificed on Day 21 and Day 28 to examine bone and joint destruction, and the hind limb was cut off at the center of the lower leg and soft radiography (CMB-2; Softex) was performed. The degree of bone and joint destruction was classified into five levels and evaluated.
- the X-ray bone and joint destruction index (RI) of this example is as follows. (0: no findings, 1: mild bone atrophy and swelling of soft shadows, 2: narrowing of joint space and moderate bone atrophy, 3: bone, cartilage bilane or moderate joint destruction, 4: severe Loss of joint structure due to bone destruction).
- Figure 3C shows the radiographic bone and joint destruction index.
- bone and joints were blocked by FGF-2 intracellular signal block at any time. Blasting was significantly suppressed.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002519414A CA2519414A1 (en) | 2003-03-19 | 2004-03-05 | Methods of treating inflammatory diseases associated with bone destruction |
AU2004222418A AU2004222418A1 (en) | 2003-03-19 | 2004-03-05 | Method of treating inflammtory disease associated with bone destruction |
JP2005503647A JPWO2004082704A1 (ja) | 2003-03-19 | 2004-03-05 | 骨破壊を伴う炎症性疾患の治療方法 |
EP04717780A EP1611900A1 (en) | 2003-03-19 | 2004-03-05 | Method of treating inflammtory disease associated with bone destruction |
US10/549,474 US20070173466A1 (en) | 2003-03-19 | 2004-03-05 | Methods of treating inflammatory diseases associated with bone destruction |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003075964 | 2003-03-19 | ||
JP2003-075964 | 2003-03-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004082704A1 true WO2004082704A1 (ja) | 2004-09-30 |
Family
ID=33027877
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/002887 WO2004082704A1 (ja) | 2003-03-19 | 2004-03-05 | 骨破壊を伴う炎症性疾患の治療方法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070173466A1 (ja) |
EP (1) | EP1611900A1 (ja) |
JP (1) | JPWO2004082704A1 (ja) |
KR (1) | KR20050114241A (ja) |
CN (1) | CN1787832A (ja) |
AU (1) | AU2004222418A1 (ja) |
CA (1) | CA2519414A1 (ja) |
WO (1) | WO2004082704A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005056791A1 (ja) * | 2003-10-30 | 2007-12-06 | 財団法人かずさディー・エヌ・エー研究所 | 新規PlexinポリペプチドとそれをコードするDNA、及びその用途 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2739011A1 (en) * | 2007-10-29 | 2009-05-07 | The Regents Of The University Of California | Osteoarthritis gene therapy |
CN104107438A (zh) * | 2014-05-29 | 2014-10-22 | 中国人民解放军军事医学科学院基础医学研究所 | Spry2在制备预防和治疗类风湿性关节炎药物中的应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07265079A (ja) * | 1991-12-02 | 1995-10-17 | Yeda Res & Dev Co Ltd | リガンド特異性を与える繊維芽細胞レセプター内のリガンド−結合決定領域 |
JP2000229883A (ja) * | 1999-02-12 | 2000-08-22 | Chemo Sero Therapeut Res Inst | 塩基性線維芽細胞増殖因子アンタゴニストを有効成分とする慢性関節リウマチ治療剤 |
JP2002500623A (ja) * | 1996-11-07 | 2002-01-08 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニヴァーシティー | スプルーティタンパク質およびコーディング配列 |
JP2003503313A (ja) * | 1999-06-03 | 2003-01-28 | ジェシー エル エス オウ | 細胞増殖及び細胞死を変調する方法及び組成物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5491220A (en) * | 1993-09-24 | 1996-02-13 | Yeda Research And Development Co., Ltd. | Surface loop structural analogues of fibroblast growth factors |
US6811788B2 (en) * | 2000-01-19 | 2004-11-02 | Baofa Yu | Combinations and methods for treating neoplasms |
-
2004
- 2004-03-05 JP JP2005503647A patent/JPWO2004082704A1/ja active Pending
- 2004-03-05 AU AU2004222418A patent/AU2004222418A1/en not_active Abandoned
- 2004-03-05 EP EP04717780A patent/EP1611900A1/en not_active Withdrawn
- 2004-03-05 US US10/549,474 patent/US20070173466A1/en not_active Abandoned
- 2004-03-05 CA CA002519414A patent/CA2519414A1/en not_active Abandoned
- 2004-03-05 WO PCT/JP2004/002887 patent/WO2004082704A1/ja not_active Application Discontinuation
- 2004-03-05 KR KR1020057017396A patent/KR20050114241A/ko not_active Application Discontinuation
- 2004-03-05 CN CNA2004800128993A patent/CN1787832A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07265079A (ja) * | 1991-12-02 | 1995-10-17 | Yeda Res & Dev Co Ltd | リガンド特異性を与える繊維芽細胞レセプター内のリガンド−結合決定領域 |
JP2002500623A (ja) * | 1996-11-07 | 2002-01-08 | ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニヴァーシティー | スプルーティタンパク質およびコーディング配列 |
JP2000229883A (ja) * | 1999-02-12 | 2000-08-22 | Chemo Sero Therapeut Res Inst | 塩基性線維芽細胞増殖因子アンタゴニストを有効成分とする慢性関節リウマチ治療剤 |
JP2003503313A (ja) * | 1999-06-03 | 2003-01-28 | ジェシー エル エス オウ | 細胞増殖及び細胞死を変調する方法及び組成物 |
Non-Patent Citations (3)
Title |
---|
WAKIOKA T, ET AL: "Spred is a sprouty-related suppressor of ras signalling", NATURE, vol. 412, no. 9, 2001, pages 647 - 651, XP002980582 * |
YAMASHITA A, ET AL: "Fibroblast growth factor-2 determines severity of joint disease in adjuvant-induced arthritis in rats.", JOURNAL OF IMMUNOLOGY, vol. 168, no. 1, 2002, pages 450 - 457, XP002980580 * |
YUSOFF P, ET AL: "Sprouty2 inhibits the Ras/MAP kinase pathway by inhibiting the activation of Raf", J. BIOL. CHEM., vol. 277, no. 5, 2002, pages 3195 - 3201, XP002980581 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005056791A1 (ja) * | 2003-10-30 | 2007-12-06 | 財団法人かずさディー・エヌ・エー研究所 | 新規PlexinポリペプチドとそれをコードするDNA、及びその用途 |
JP4751202B2 (ja) * | 2003-10-30 | 2011-08-17 | 財団法人かずさディー・エヌ・エー研究所 | 新規PlexinポリペプチドとそれをコードするDNA、及びその用途 |
Also Published As
Publication number | Publication date |
---|---|
CA2519414A1 (en) | 2004-09-30 |
KR20050114241A (ko) | 2005-12-05 |
AU2004222418A1 (en) | 2004-09-30 |
JPWO2004082704A1 (ja) | 2006-06-22 |
CN1787832A (zh) | 2006-06-14 |
EP1611900A1 (en) | 2006-01-04 |
US20070173466A1 (en) | 2007-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2001288111A (ja) | 腎疾患治療剤 | |
ES2770073T3 (es) | Uso terapéutico de proteínas morfogenéticas óseas | |
JP2017527294A (ja) | Mir−29模倣物およびその使用 | |
EP2034014A1 (en) | Therapeutic agent for alzheimer's disease | |
US20060263422A1 (en) | Pharmaceutical composition containing decoy and use of the same | |
JP2001515360A (ja) | ▲II▼型TGF−βレセプター/免疫グロブリン定常領域融合タンパク質 | |
BR122016021558A2 (pt) | Polipeptídeos isolados, seus usos, e composição farmacêutica | |
RU2672341C2 (ru) | Применение пептида для лечения сердечно-сосудистых заболеваний | |
KR20030074627A (ko) | 혈관신생 유전자를 코드하는 파라믹소바이러스 벡터 및 그 이용 | |
JPWO2005087269A1 (ja) | 腫瘍増殖を抑制する方法 | |
KR20010040906A (ko) | 각질세포 성장 인자-2의 치료학적 용도 | |
Wen et al. | Glucocorticoids modulate TGF-β production | |
WO2013076344A1 (es) | Ingeniería de células madre y su uso terapeutico | |
WO2004084934A1 (ja) | 喘息治療剤 | |
WO2004082704A1 (ja) | 骨破壊を伴う炎症性疾患の治療方法 | |
US20070036756A1 (en) | Method for treating ischemic diseases | |
JP2018533974A (ja) | 医薬としてのヒト由来免疫抑制タンパク質およびペプチドの使用 | |
US20030228283A1 (en) | Preventing secondary lymphedema with VEGF-D DNA | |
EP2268302B1 (en) | Bmp-7 for use in treating neointimal hyperplasia | |
ES2390763T3 (es) | Fragmentos peptídicos del factor HARP que inhiben la angiogénesis | |
KR20230022159A (ko) | 염증의 치료에 사용하기 위한 3-아자-바이사이클[3.2.1]옥탄 카복실산 및 이의 유도체 | |
WO2018183127A1 (en) | Mir-92 inhibitors for treatment of heart failure | |
ES2765259T3 (es) | Polirribonucleótido estabilizado que codifica una proteína de fibra elástica | |
JP2021506268A (ja) | 心不全を治療するための改善された化合物 | |
JPH06312941A (ja) | Hgf産生促進剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005503647 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004222418 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2519414 Country of ref document: CA Ref document number: 1020057017396 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2004222418 Country of ref document: AU Date of ref document: 20040305 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004222418 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004717780 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048128993 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057017396 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004717780 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007173466 Country of ref document: US Ref document number: 10549474 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10549474 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004717780 Country of ref document: EP |